Roche’s Accu-Chek SugarView app may disrupt India’s blood glucose monitoring market, says GlobalData, a leading data and analytics company.
Global Data’s report, ‘Diabetes Care Devices—Insulin Pens—Global—2015-2028’, reveals that the prevalence of type 2 diabetes in India is expected to grow from 8.8% in 2019 to 9.4% in 2028.
“The rising cases are creating an unmet need for diagnosis, care and management of diabetic population in India. Monitoring diabetes digitally through an app will impact a large population and this could be a path-breaking solution for the diagnosis and management of diabetes in the long run,” says Rohit Anand, Medical Devices Analyst at GlobalData.
A very large mobile using population in India provides an equally large market opportunity to mobile health app developing companies. The currently available diabetes apps in India are used primarily to monitor blood glucose level trends and an individual needs to input these data points manually.
Accu-Chek SugarView on the other hand can determine blood glucose ranges with the help of photos using a smartphone camera and test strips, without the need of a blood glucose meter. It will help non-insulin-dependent type 2 diabetics or pre-diabetics lead healthier lives. Roche recently received CE approval for the app.
“Roche’s Accu-Chek SugarView app could disrupt the glucose monitoring devices market in India. Ease of use and accuracy of test results will surely encourage people to use this app,” says Rohit.
Follow The Indian Sun on Twitter.
#Roche has recently received CE approval for its Accu-Chek SugarView blood glucose monitoring #app, allowing the company to market #glucose monitoring products aggressively and further strengthen its leadership position in #India. #TheIndianSun #Diabeteshttps://t.co/HWoJxZlt3U
— The Indian Sun (@The_Indian_Sun) January 28, 2020